TAFAZZIN and Barth syndrome: Furthermore, understanding the diverse mitochondrial effects caused by tafazzin deficiency has important implications for development of therapeutics, for example, CI targeting agents may not be sufficient to remediate cardiac or skeletal muscle abnormalities in BTHS, where underlying defects in mitophagy and apoptosis are prominent tafazzin-deficient–associated abnormalities.